ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared ProKidney Corp. (PROK) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 326,686.02 | 19,176.16 | 1,230.81 | 751.11 | 991.09 | 0.00 | 30.0675 | 43.81 | -0.7205 | -18.9188 | -0.07 | -0.08 | 6.1493 | - - | ||
| Maximum | - - | - - | - - | 39,663,781.00 | 881,933.00 | 85,592.00 | 99,050.00 | 262,089.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -233.7460 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| DICE Therapeutics, Inc. DICE | 47.55 | 0.03 0.06% | 4,332 vs. 1,753 | 2,270.00 | 0.00 | -34.00 | -30.00 | -248.00 | -0.7400 | -15.7831 | 0.0000 | 0.0000 | 0.0000 | -0.0671 | -0.0632 | 25.6858 | 47.00 | ||
| Vaxcyte, Inc. PCVX | 86.21 | 0.46 0.54% | 1,122 vs. 1,081 | 10,744.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.0000 | 0.0000 | 0.0000 | -0.0479 | -0.0454 | 17.2498 | 124.00 | ||
| ProKidney Corp. PROK | 1.46 | -0.08 -4.89% | 483 vs. 614 | 425.00 | 0.00 | -9.00 | -35.00 | -1,149.00 | -0.1600 | -2.5686 | 0.0000 | 0.0000 | 0.0000 | 0.0087 | -0.0245 | 17.1442 | 291.00 | ||
| Revolution Medicines, Inc. RVMD | 43.29 | 0.32 0.74% | 1,599 vs. 1,590 | 7,893.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 182.00 | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.